Spider silk nerve repair

Why Investors Should Care

The current nerve repair market is underserved by existing technologies that are either invasive, expensive, supply-constrained, or clinically limited. A successful spider silk nerve conduit platform would address a major gap in treatment, unlock new possibilities in regenerative medicine, and position the company at the forefront of a high-value biomaterials category. In other words, this is not only a scientific opportunity, it is a chance to build a platform technology with strong clinical relevance, commercial scalability, and global impact.


Our Opportunity

This is where our project stands apart. We are developing a spider silk–based nerve conduit platform designed to overcome the core limitations of current solutions. Our goal is to create a conduit that is not only highly biocompatible and structurally supportive of nerve regeneration, but also commercially scalable and suitable for broader clinical adoption. In the near term, we are focused on peripheral nerve repair; in the long term, we see the platform expanding into spinal cord injury and other advanced regenerative medicine applications.

By solving a real clinical problem with a differentiated biomaterial approach, we believe this project has the potential to create both meaningful patient impact and significant long-term market value.

The project is designed to develop a spider silk–based peripheral nerve conduit prototype and generate a strong proof-of-concept dataset within three years. Upon securing funding, we will promptly commence work, concentrating on three primary areas.

First, we will fabricate the initial batch of peripheral nerve conduit samples and establish the foundational production workflow.
Second, we will validate the biological and structural performance of the conduits through targeted testing, including assessments of material behavior, structural integrity, and suitability for nerve repair applications. Third, we will create an IP “anchor” by documenting the invention thoroughly and initiating the first IP protection steps, helping to safeguard the technology, strengthen investor confidence, and reduce future infringement risk.

This first funding round is intended to create the technical and intellectual property foundation needed for the next stage of development, positioning the project for larger follow-on funding and future partnership opportunities.

Why the Market Needs a Better Solution
1. Autografts remain the gold standard — but they come at a cost

Autologous nerve grafting is still considered the clinical gold standard for repairing significant peripheral nerve gaps. In this procedure, a patient’s own nerve, often a sensory nerve such as the sural nerve, is harvested and used to bridge the damaged area. Autografts are effective because they provide a natural extracellular matrix and aligned internal architecture that supports axonal regeneration.

However, this method is also a double-edged solution. It creates a second surgical injury site and may lead to permanent donor-site morbidity, including sensory loss, neuropathic pain, and functional deficits. In addition, donor nerve tissue is limited, making it difficult to treat very long or multiple nerve gaps. Autografting also increases surgical time, procedural complexity, and overall burden on both the patient and the healthcare system.

2. Processed nerve allografts improve convenience — but not scalability

Processed nerve allografts, derived from cadaveric tissue, have emerged as an alternative to autografts. Because they are decellularized to reduce immunogenicity while preserving the native nerve scaffold, they can function as off-the-shelf implants and have shown meaningful clinical utility in selected peripheral nerve repairs.

That said, allografts still face major commercial and clinical constraints. They are expensive, depend on a limited supply of donated human tissue, and require specialized processing, storage, and cold-chain logistics. Although disease transmission risk is low, it is not entirely eliminated, and variation in graft quality may affect consistency and surgeon confidence. These limitations make allografts difficult to scale globally, especially in cost-sensitive healthcare markets.

3. Synthetic conduits are available — but often insufficient for major injuries

Synthetic and biologic nerve conduits made from collagen or biodegradable polymers are attractive because they avoid donor-site morbidity and are easier to manufacture. Several products are already used clinically for short-gap repairs.

However, these materials often fall short in more severe cases. Some synthetic conduits may trigger inflammation, fibrotic encapsulation, or foreign body responses if their degradation profile is not well matched to the pace of nerve regeneration. As a result, they are generally not the preferred option for major nerve injuries, and the field continues to rely on autografts for clinically significant nerve gaps. This leaves a substantial unmet need for a more effective long-gap repair technology.

Our Spider Silk Nerve Conduit directly addresses the above problems by offering a biologically inspired, off-the-shelf graft substitute that combines the regenerative guidance of a nerve autograft with the convenience of a synthetic conduit. The core value proposition of our solution is that it can deliver superior nerve regeneration outcomes without the trade-offs that burden current standards of care.

Spinal Cord Repair: A Breakthrough Opportunity for Spider Silk Conduits.

Spinal cord injury remains one of the most urgent and underserved challenges in regenerative medicine. Unlike peripheral nerve repair, the spinal cord presents a far more complex regenerative environment, where scar formation, inhibitory signaling, and the lack of structural guidance severely limit natural recovery. Therefore, current treatment pathways prioritize stabilization and rehabilitation over true biological repair.

This is exactly where our platform made of spider silk conduits creates a compelling opportunity. We think that spider silk is a very promising material for repairing the spinal cord because it is biocompatible, strong, flexible, and naturally good at guiding neural regeneration. These properties position spider silk as a highly differentiated biomaterial platform for building next-generation conduits designed to support reconnection across severe neural injuries.

Our long-term vision is to extend this platform beyond peripheral nerve repair and into spinal cord injury applications, where the clinical need is far greater and the impact could be transformational. If successfully translated, spider silk spinal cord repair conduits could represent a major step forward in addressing one of the most difficult problems in modern medicine, helping patients move beyond stabilization alone and toward meaningful functional recovery.

In that sense, this is not simply an incremental product opportunity. It is a platform with the potential to open a new category in regenerative neurorepair, combining strong scientific differentiation with significant long-term clinical and commercial value.